癌-睾丸抗原CT57促进肝癌细胞增殖、侵袭、迁移和上皮间质转化
Promotive effect of cancer-testis antigen CT57 on proliferation, invasion, migration and epithelial-mesenchymal transition of liver cancer cells
Note： A. CT57 expression levels of different tumor types in the TCGA database. BLCA—bladder urothelial carcinoma; BRCA—breast invasive carcinoma; CHOL—cholangiocarcinoma; COAD—colon adenocarcinoma; ESCA—esophageal carcinoma; HNSC—head and neck squamous cell carcinoma; KICH—kidney chromophobe; KIRC—kidney renal clear cell carcinoma; KIRP—kidney renal papillary cell carcinoma; LIHC—liver hepatocellular carcinoma; LUAD—lung adenocarcinoma; LUSC—lung squamous cell carcinoma; PRAD—prostate adenocarcinoma; READ—rectum adenocarcinoma; STAD—stomach adenocarcinoma; THCA—thyroid carcinoma; UCEC—uterine corpus endometrial carcinoma. The expression of CT57 in the liver cancer is marked by the red box. B. Kaplan-Meier survival curves comparison between the liver cancer patients with high expression and low expression of CT57 in livers. C. The mRNA expression levels of CT57 in cell lines. D. Western blotting analysis of CT57 expression level in four human liver cancer cells.
